间充质干细胞治疗急性肺损伤的研究进展

Research advances of mesenchymal stem cells in acute lung injury

背景急性肺损伤（acutelunginjury，ALI）是由直接或间接损伤因素导致的临床危重症，表现为急性进行性低氧血症及肺水肿，目前尚缺乏有效的治疗方法，病死率高达30％～50％。间充质干细胞（mesenchymalstemcell，MSC）是一种具有体外增殖和分化潜能的多功能干细胞，大量基础实验发现，MSC对ALI有损伤修复、免疫调节、抗炎等治疗作用。目的综述MSC的特性、常用来源、使用方法、治疗Au的作用机制及临床运用潜能。内容MSC通过植入和归巢、免疫调节、降低肺水肿、抗菌作用、线粒体转移和微泡、微管形成等潜在机制治疗Au。趋向MSC对人ALI的治疗作用需要大样本试验，MSC治疗疾病的最佳移植时机、最适剂量、最利移植方式及评估未有统一标准，是否存在一些弊端也有待研究证明。

Background The acute lung injury （ALl） is a common critical disease in clinics, which is caused by direct or indirect injuries. The main characteristics are acute pulmonary edema and hyoxemia. ALI is still lack of effective therapy method. The mortality is about 30%-50%. Mesenchymal stem cells （MSC） are pluripotential stem cell, which have the basic ability of proliferation and differentiation. MSC can treat the acute lung injury due to its reparation role of damage, immunoregulation and anti-inflammation. Objective Summarizing the characteristics, common sources and usages of MSC. Verifying the mechanism and potential clinical utility of MSC in the therapy of acute lung injury. Content Through implantation, homing and immunoregulation, reducing pulmonary edema, antibiotic action, transference of mitochondria and formation of microvesicle and mierotubule, MSC play a therapeutic role on ALL Trend Large scale clinical trials are needed to prove that MSC can cure the ALL The optimum time, mode, and dosage of transplantation have no unified standard yet. Whether there are some drawbacks remains to be test.